TLR9 and cancer: Both TLR4 agonist GLA-SE and TLR9 agonist CpG-C oligodeoxynucleotides significantly decrease cancer metastasis by increasing NK cell cytotoxicity during the perioperative period in a mouse model without adverse effects [142, 143].